TGF-beta-1 (transforming growth factor beta 1)
Pro-fibrotic and immunomodulatory cytokine; abnormally elevated in CIRS, particularly in cases exposed to actinobacteria; serves as objective biomarker for disease severity and endotoxin exposure; improves with treatment
As defined in Worse Than Asbestos? The CIRS Rabbit Hole | Dr. Scott McMahon & Dr. Ritchie Shoemaker | EP 415
Where it comes up · 1
- Worse Than Asbestos? The CIRS Rabbit Hole | Dr. Scott McMahon & Dr. Ritchie Shoemaker | EP 4152 claims
Most important claims · 2 of 2Search all claims for “TGF-beta-1 (transforming growth factor beta 1)” →
- The primary biomarkers used to diagnose CIRS are: (1) Visual Contrast Sensitivity (VCS) test—abnormally low sensitivity indicating retinal microcirculation dysfunction; (2) HLA-DR genetic susceptibility; (3) Melanocyte-stimulating hormone (MSH)—abnormally low; (4) Cytokine levels—abnormally elevated; (5) TGF-beta-1 (transforming growth factor beta 1)—abnormally elevated. These biomarkers are chosen because they are validated to separate cases from healthy controls and show objective improvement with treatment.Worse Than Asbestos? The CIRS Rabbit Hole | Dr. Scott McMahon & Dr. Ritchie Shoemaker | EP 415
- A rheumatologist at University of Washington initially resisted testing for TGF-beta-1 in a juvenile rheumatoid arthritis patient who was going blind; Shoemaker noted there are 75,000 published papers on TGF-beta-1, indicating the marker exists in peer-reviewed literature. After testing, TGF-beta-1 was found to be elevated and was causative; treatment normalized it and the patient regained vision.Worse Than Asbestos? The CIRS Rabbit Hole | Dr. Scott McMahon & Dr. Ritchie Shoemaker | EP 415